Table 4. Overview of significantly involved pathways in patients’ progressive disease on afatinib and the involved mutated genes.
| Nr. of patient sample | N/P/R | N/R | N/P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| #2 | #5 | #6 | #1 | #4 | #7 | #3 | ||||
| A | B | A | B | A | B | C | C | C | D | |
| Pathway | ||||||||||
| Glycolysis | ADPGK | LDH6A | ||||||||
| Autophagy | ||||||||||
| IL6/JAK/STAT | ||||||||||
| Wnt | MAPK8 | TP53 | TP53 | FOSL1 | PLCB4 | WNT9B | INVS | AXIN1 | TP53 | |
| LEF1 | TP53 | TP53 | ||||||||
| FZD10 | ||||||||||
| APC2 | ||||||||||
| PI3K-AKT | COL4A4 | ITGA2 | PPP2R2B | EGFR | LAMC3 | EGF | EGFR | EGFR | TP53 | KDR |
| EGFR | PIK3CA | EGFR | LAMB3 | FASLG | RELN | |||||
| VWF | PIK3CG | COL1A2 | PTEN | FASLG | ||||||
| TSC2 | COL4A5 | FASLG | TP53 | |||||||
| TP53 | TP53 | |||||||||
A: resistant biopsy specific based on MRF R >2x MRF P, B: mutation present in both pre and post afatinib biopsy based on MRF R <2x MRF P and MRF R > 0. C: mutation in resistant biopsy based on MRF R > 0, D: mutation in pre-afatinib biopsy in non-responding patient based on MRF P > 0; italic: present in other primary samples. N: normal tissue or buffy coat, P: biopsy before afatinib treatment, R: biopsy after afatinib treatment.